MASH Treatment Enters a New Era With Approved Drugs and Personalized Strategies
A landmark Nature review maps the full therapeutic landscape of MASH, from newly approved drugs to emerging combination therapies targeting fibrosis, inflammation, and metabolic dysfunction.
Summary
Metabolic dysfunction-associated steatohepatitis (MASH) is the aggressive form of fatty liver disease that can progress to cirrhosis, liver cancer, and cardiovascular disease. This major Nature review surveys the rapidly evolving treatment landscape following two landmark drug approvals: resmetirom (a thyroid hormone receptor-β agonist) and semaglutide (a GLP-1 receptor agonist), both now cleared for non-cirrhotic MASH with fibrosis. The authors highlight that MASH is not one disease but several overlapping subtypes — some driven by rapid fibrosis, others by cardiometabolic risk — meaning one-size-fits-all treatment is unlikely to succeed. Emerging therapies targeting PPAR receptors, FGF21 pathways, incretin and glucagon signaling, gut-liver axis dysfunction, and inflammatory cascades are in the pipeline. The review argues that advances in disease phenotyping and biomarkers now make precision, stratified, and combination therapy approaches achievable.
Detailed Summary
Metabolic dysfunction-associated steatohepatitis (MASH) has moved from a condition with no approved treatments to one with two pharmacological options in just a few years — a pivotal shift in hepatology and metabolic medicine. Because MASH increases risk not only for liver cirrhosis and hepatocellular carcinoma but also for cardiovascular disease and chronic kidney disease, effective management has enormous implications for healthspan and longevity.
This comprehensive review in Nature, authored by an international team of leading hepatologists and metabolic scientists, synthesizes the current therapeutic landscape and charts a path toward personalized treatment. The authors trace how over a decade of late-stage clinical trials produced two FDA-approved agents: resmetirom, which targets thyroid hormone receptor-β to reduce hepatic fat and fibrosis, and semaglutide, which activates GLP-1 receptors to improve metabolic dysfunction and liver histology in non-cirrhotic patients.
A central insight is that MASH is heterogeneous. The authors identify distinct disease subsets: liver-centric phenotypes with accelerated fibrogenesis and a higher risk of liver-related outcomes, and cardiometabolic phenotypes dominated by insulin resistance and elevated cardiovascular risk. This biological diversity suggests that single-agent, universal approaches will be inadequate for many patients. Stratified treatment — matching therapy to phenotype — and rational combination regimens will likely be required.
Beyond approved agents, the review catalogs an expanding pipeline: PPAR agonists, FGF21 analogues, incretin-based and glucagon-receptor-based therapies, anti-fibrotic agents, anti-inflammatory strategies, and gut-liver axis modulators. Biomarker development is accelerating in parallel, potentially allowing clinicians to match patients to the right treatment without relying solely on invasive liver biopsy.
For the longevity-focused audience, MASH represents a major convergence point of metabolic health, inflammation, fibrosis biology, and cancer risk. This review is an authoritative guide to where treatment is now and where precision hepatology is heading.
Key Findings
- Resmetirom and semaglutide are now the first approved pharmacotherapies for non-cirrhotic MASH with fibrosis.
- MASH comprises distinct subtypes — fibrosis-dominant and cardiometabolic-dominant — requiring stratified treatment approaches.
- Combination therapies targeting multiple pathways simultaneously are likely needed for optimal outcomes in many patients.
- Emerging agents include FGF21 analogues, PPAR agonists, and incretin/glucagon-based therapies in late-stage trials.
- Advances in non-invasive biomarkers may soon enable personalized MASH treatment without reliance on liver biopsy.
Methodology
This is a comprehensive narrative review published in Nature, synthesizing evidence from over a decade of late-stage clinical trials and mechanistic studies in MASH and MASLD. The authors represent major academic hepatology, metabolism, and cancer-biology centers across Europe and North America. As a review article, it does not report original experimental data but critically appraises and synthesizes existing trial evidence, biomarker science, and disease phenotyping data.
Study Limitations
This summary is based on the abstract only, as the full text is not open access; granular trial data, specific biomarker cut-offs, and detailed mechanistic discussions could not be reviewed. As a narrative review, it may reflect author perspective and selection bias in the literature chosen. Many of the emerging pipeline therapies discussed have not yet achieved full regulatory approval, and long-term efficacy and safety data remain incomplete.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: